Uncategorized

Updated results from the BEGONIA phase 1b/2 trial for the cohort of patients treated with datopotamab deruxtecan plus durvalumab showed that the combination demonstrated durable tumor responses and no new safety signals in patients with previously untreated advanced or metastatic triple negative breast cancer with six months additional follow-up from the previous data cut-off.

Amgen announced data from the global Phase 3 CodeBreaK 300 trial evaluating two doses of LUMAKRAS® in combination with Vectibix®.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from the final analysis of the Phase 3 MAGNITUDE study.

Seagen Inc. and Genmab A/S announced results from the Phase 3 innovaTV 301 randomized global trial, which showed treatment with TIVDAK demonstrated a statistically significant and clinically meaningful 30% reduction in the risk of death in recurrent or metastatic cervical cancer patients with disease progression on or after first-line therapy, compared with chemotherapy.

The non-alcoholic steatohepatitis space is still a “big mystery,” analysts tell BioSpace, but its connection to weight loss could provide an additional opportunity for contenders.

AI and machine learning could transform drug discovery, but first, practitioners must overcome ethical challenges en route to medicines for all.

While sensitive and specific biomarkers for Alzheimer’s disease have recently taken a leap forward, the Parkinson’s space has lagged behind. Neurofilament Light Chain could change that.

Avances recientes en la comprensión de la patogénesis y los paradigmas de tratamiento.

SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced the presentation of pivotal data from its oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2023.

Una investigación reciente ha permitido identificar dos nuevas opciones de tratamiento prometedoras para hombres con cáncer de próstata recurrente. En comparación con el tratamiento estándar actual, ambas opciones ayudaron a los pacientes a vivir más tiempo …